The purpose of this study is to compare the bioequivalence of a test formulation of primidone tablets to an equivalent oral dose of the commercially available Mysoline(primidone tablets) in adult subjects under fasting conditions.

• Experimental: One tablet containing 50mg of test product to be administered at hour 0 on Day 1 of each test period
• Active Comparator: One Mysoline tablet containing 50mg reference product to be administered at hour 0 on Day 1 of each test period

Inclusion Criteria:

• male or female
• at least 18 years of age
• weight must be 15% of ideal weight for height and frame
• subjects must be in good health and physical condition as determined by medical history
• subjects must read and sign consent form

Exclusion Criteria:

• history of treatment for alcoholism, substance abuse, or drug abuse within the last 24 months
• history of malignancy, stroke, diabetes, cardiac, renal or liver disease
• history of GERD, malabsorption syndrome, colon cancer, chronic colitis, including Crohn's disease
• history of porphyria, hyperkinesia, respiratory diseases (eg. asthma, emphysema, difficulty breathing, pulmonary obstruction)
• females who pregnant or lactating
• history of hypersensitivity to primidone, barbiturates, and anticonvulsants
• sitting systolic blood pressure below 90mm Hg, or diastolic pressure below 50mm Hg
• heart rate less than 50 beats per minute after a 5 minute rest
• treatment with any other investigation drug during the four weeks prior to initial dosing
• subjects who have donated blood within four weeks prior to the initial dosing
• subjects who smoke or use tobacco products or nicotine products. Three months abstinence is required.